Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V. Madhavan, Benjamin W. Van Tassell, David Jimenez, Manuel Monreal, Muthiah Vaduganathan, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A. Parikh, Deepak L. Bhatt, View ORCID ProfileGregory YH Lip, Gregg W. Stone, View ORCID ProfileHarlan M. Krumholz, Peter Libby, Samuel Z. Goldhaber, Behnood Bikdeli
doi: https://doi.org/10.1101/2021.05.03.21256468
Azita H. Talasaz
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
PharmDParham Sadeghipour
4Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
MDMaryam Aghakouchakzadeh
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
PharmDIsaac Dreyfus
5NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
MDHessam Kakavand
1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
PharmDHamid Ariannejad
2Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
MDAakriti Gupta
5NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
6Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
7Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, USA
MD, MSMahesh V. Madhavan
5NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
6Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
MD, MSBenjamin W. Van Tassell
3Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
8Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
PharmDDavid Jimenez
9Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain
MD, PhDManuel Monreal
10Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain
MD, PhDMuthiah Vaduganathan
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MD, MPHJohn Fanikos
12Department of Pharmacy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
R.Ph, MBADave L Dixon
3Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
8Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
PharmDGregory Piazza
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MD, MSSahil A. Parikh
5NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York
6Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
MDDeepak L. Bhatt
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MD, MPHGregory YH Lip
13Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom
14Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
MDGregg W. Stone
6Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA
15Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
MDHarlan M. Krumholz
7Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, USA
16Department of Health Policy and Administration, Yale School of Public Health, New Haven, CT, USA
17Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
MD, SMPeter Libby
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MDSamuel Z. Goldhaber
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MDBehnood Bikdeli
7Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, USA
8Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA
11Division of cardiovascular Medicine Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
MD, MS
Data Availability
Data availability only after permission of corresponding author
Posted May 05, 2021.
Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V. Madhavan, Benjamin W. Van Tassell, David Jimenez, Manuel Monreal, Muthiah Vaduganathan, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A. Parikh, Deepak L. Bhatt, Gregory YH Lip, Gregg W. Stone, Harlan M. Krumholz, Peter Libby, Samuel Z. Goldhaber, Behnood Bikdeli
medRxiv 2021.05.03.21256468; doi: https://doi.org/10.1101/2021.05.03.21256468
Lipid-Modulating Agents for Prevention or Treatment of COVID-19 in Randomized Trials
Azita H. Talasaz, Parham Sadeghipour, Maryam Aghakouchakzadeh, Isaac Dreyfus, Hessam Kakavand, Hamid Ariannejad, Aakriti Gupta, Mahesh V. Madhavan, Benjamin W. Van Tassell, David Jimenez, Manuel Monreal, Muthiah Vaduganathan, John Fanikos, Dave L Dixon, Gregory Piazza, Sahil A. Parikh, Deepak L. Bhatt, Gregory YH Lip, Gregg W. Stone, Harlan M. Krumholz, Peter Libby, Samuel Z. Goldhaber, Behnood Bikdeli
medRxiv 2021.05.03.21256468; doi: https://doi.org/10.1101/2021.05.03.21256468
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (202)
- Cardiovascular Medicine (2954)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12762)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4597)
- Geriatric Medicine (420)
- Health Economics (730)
- Health Informatics (2931)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (925)
- Medical Education (427)
- Medical Ethics (116)
- Nephrology (470)
- Neurology (4371)
- Nursing (237)
- Nutrition (640)
- Oncology (2276)
- Ophthalmology (647)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1197)
- Primary Care Research (499)
- Public and Global Health (6960)
- Radiology and Imaging (1531)
- Respiratory Medicine (915)
- Rheumatology (440)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (181)